» Articles » PMID: 19925256

Alginate-antacid Combinations: Raft Formation and Gastric Retention Studies

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2009 Nov 21
PMID 19925256
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Alginate-based gastroesophageal reflux disease treatments have been used extensively and fall into two main categories. Those containing alginate as the principle active agent and those containing alginate in combination with a significant amount of antacid.

Method: The effectiveness of the raft formed by a new alginate/antacid suspension (Gaviscon Double Action Liquid, GDAL), in which calcium carbonate was the main antacid ingredient, was compared with those of existing alginate/antacid suspensions.

Result: GDAL had similar raft strength and improved raft resilience than Gaviscon Liquid (GL), and both were significantly greater than five other products tested. Gastric retention of GDAL was similar to that of GL.

Conclusion: the in vitro and in vivo performance is maintained in the new GDAL formulation even with higher antacid levels and the product is as good as, or better than, previous formulations.

Citing Articles

Current Developments in the Delivery of Gastro-Retentive Drugs.

Shah K, Singh D, Agrawal R, Garg A AAPS PharmSciTech. 2025; 26(2):57.

PMID: 39920556 DOI: 10.1208/s12249-025-03052-4.


Oral co-polymeric raft-forming nano gels for targeted empagliflozin delivery against stomach cancer (SGC7901).

Alhakamy N, Abdullah S, Md S, Ansari A, Bhattamisra S, Ibrahim I Heliyon. 2024; 10(13):e34074.

PMID: 39071709 PMC: 11279758. DOI: 10.1016/j.heliyon.2024.e34074.


Expanding the Manufacturing Approaches for Gastroretentive Drug Delivery Systems with 3D Printing Technology.

Turac I, Porfire A, Iurian S, Crisan A, Casian T, Iovanov R Pharmaceutics. 2024; 16(6).

PMID: 38931911 PMC: 11207633. DOI: 10.3390/pharmaceutics16060790.


Review of recent evidence on the management of heartburn in pregnant and breastfeeding women.

Ali R, Hassan J, Egan L BMC Gastroenterol. 2022; 22(1):219.

PMID: 35508989 PMC: 9066781. DOI: 10.1186/s12876-022-02287-w.


Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications.

Vrettos N, Roberts C, Zhu Z Pharmaceutics. 2021; 13(10).

PMID: 34683884 PMC: 8539558. DOI: 10.3390/pharmaceutics13101591.